It results in implantation of donor microbiota into recipients and restoration of normal distal gut microbial
community
structure. We anticipate that this form of therapy represents merely the first entry into a new
class
of therapeutics. There is great interest in application of FMT or defined microbial consortia to treat-
ment
of many diseases associated with dysbiosis. However, many challenges remain in development as
our
understanding of microbial ecology within the human body and microbiota–host interactions remain
limited.
Futureadvancesinthisfieldwillbecriticallydependingondetailedmechanisticunderstanding.